retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, an experimental weight-loss drug, has not been approved by the FDA. But, doctors and nurse practitioners in clinics across the country are prescribing it anyway, a CBS News investigation Mazdutide vs retatrutide: dual agonist

When you eat 16-39% fewer calories, as research shows most GLP-1 users do, you simultaneously consume fewer essential nutrients

Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial

Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits

Notably, the levels of these markers were significantly and progressively reversed in groups A3-A5, suggesting that dulaglutide may effectively suppress uremic toxic substance-induced oxidative stress and inflammation, particularly at higher dosages

Frontal brain asymmetry and reward responsiveness: A Source localization study

Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain